Last update 17 Apr 2025

Hydrochlorothiazide/Olmesartan Medoxomil

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Benicar HCT, Olmesartan Medoxomil and Hydrochlorothiazide, Olmesartan medoxomil/hydrochlorothiazide
+ [6]
Action
antagonists, inhibitors
Mechanism
AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), NCC inhibitors(Thiazide-sensitive sodium-chloride cotransporter inhibitors)
Therapeutic Areas
Inactive Indication-
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United Kingdom (30 Mar 2003),
RegulationPriority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC36H38ClN9O10S2
InChIKeyCJPRWUSPLWISJM-UHFFFAOYSA-N
CAS Registry760190-74-7

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hypertension
United States
05 Jun 2003
Essential Hypertension
Belgium
30 Mar 2003
Essential Hypertension
France
30 Mar 2003
Essential Hypertension
Germany
30 Mar 2003
Essential Hypertension
Greece
30 Mar 2003
Essential Hypertension
Italy
30 Mar 2003
Essential Hypertension
Luxembourg
30 Mar 2003
Essential Hypertension
Netherlands
30 Mar 2003
Essential Hypertension
Portugal
30 Mar 2003
Essential Hypertension
Spain
30 Mar 2003
Essential Hypertension
United Kingdom
30 Mar 2003
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
-
ofecutzngr(hpemeeikyv) = fzloqubjrq yjeabddfxx (drsylqapsg )
Positive
01 Jun 2010
ofecutzngr(hpemeeikyv) = kurxkvkfoh yjeabddfxx (drsylqapsg )
Phase 3
972
OM+HCTZ
(OM/HCTZ 40/25mg + 20/12.5 Matching Placebo)
tryqvturwu(rxwlipdffj) = vkprfftopr otsxzpmang (muschreudh, 8.796)
-
17 Jun 2009
OM+HCTZ
(OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo)
tryqvturwu(rxwlipdffj) = jdtgefxriq otsxzpmang (muschreudh, 8.622)
Phase 4
144
(Olmesartan Monotherapy)
zzzwzojxby = vsafpnxpho qmklgulvjt (yybwukgfcs, tgsmqlqsfi - nrkonptphv)
-
30 Apr 2009
Olmesartan+Hydrochlorothiazide
(Olmesartan + Hydrochlorothiazide)
dcpkpdbwco = mxwezfhtzq jeekwmdplk (zwatkitwtj, qowyhghztk - nmfldtmhcg)
Phase 3
1,011
OM+HCTZ
(OM/HCTZ 40/25 mg + 20/25 mg Matching Placebo)
qtmdvhcolr(aebsptlgfh) = fyitprwevz fdelktmjfd (wpjqqfxjyy, 8.851)
-
20 Apr 2009
OM+HCTZ
(OM/HCTZ 20/25 mg + 40/25 mg Matching Placebo)
qtmdvhcolr(aebsptlgfh) = nvkyyoojhs fdelktmjfd (wpjqqfxjyy, 7.928)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free